A pipeline of innovation and hope
![PTC Pipeline - December 2024](https://www.ptcbio.com/wp-content/uploads/sites/2/2025/01/PTC_Pipeline_2024_Dec24-scaled.jpg)
Approved Medicines
PTC has been a pioneer in the development of breakthrough rare disease therapies, delivering a number of firsts for patients who previously had no other treatment options. Our strategy leverages our innovative scientific knowledge, our deep therapeutic expertise and robust global commercial infrastructure. See below for a list of our approved/authorized products. Please note, our products are approved in individual countries for specific uses and the information provided is governed by local regulations. The name, availability and indication of these medicines may vary by country.
![Emflaza logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2022/12/emflaza.gif)
![Evrysdi logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2023/07/Evrysdi.png)
![Tegsedi logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2023/07/Tegsedi.png)
![Translarna logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2022/12/translarna.gif)
![Upstaza logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2022/12/upstaza.gif)
![Waylivra logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2023/03/waylivra.png)
![Kebilidi Logo](https://www.ptcbio.com/wp-content/uploads/sites/2/2025/01/KebilidiLogo_Positive_RGB-707x478-1828a8b.png)
U.S. Expanded Access Policy
At PTC we are committed to providing novel treatment options to patients living with serious diseases. To do this, we conduct clinical trials to assess the safety and efficacy of investigational medicines, which may allow us to obtain the necessary regulatory approvals and provide patients with broader access to these medicines.